Helicobacter Pylori Infection Among Women With Recurrent Abortion of Unknown Cause

December 6, 2025 updated by: Mostafa Gamal Ahmed Mostafa, Assiut University

H.Pylori Infection Among Women With Recurrent Abortion of Unknown Cause

  • Helicobacter pylori (H. pylori) infection affects approximately one half of the world population and it is more prevalent in developing countries. This microorganism colonizes the stomach. Typically, it is acquired during childhood and causes asymptomatic chronic infection. A small portion of H. pylori infected subjects develop peptic ulcers and gastric carcinoma, usually during late adulthood. (1,2)
  • Some studies show a relationship between H.pylori and pregnancy-related disorders, such as fetal growth defects and malformations, miscarriage and, more recently, to pre-eclampsia. (3)
  • Abortion is one of the most common complications of pregnancy. Infection is one of the main causes of abortion, a cause which is more important in spontaneous abortion; infections account for only 5% of recurrent abortions. (4)
  • The severity of infection with H.pylori: given the increasing secretion of inflammatory cytokines and CD8 +, CD4 + in T cells and increasing interferons (IFN), studies have shown that infection with Helicobacter pylori activates immune cells in the uterus and endometrial surface cells, increases TH1 response to helicobacter, disturbs the ratio of T-Helper 2 / T-Helper 1 cytokines, causes abnormalities in the formation of natural vessels in the uterus and, ultimately, leads to abortion.(5)
  • Repeated spontaneous abortion (RSA): >=2 consecutive spontaneous pregnancy losses before 20 weeks gestation.(6)
  • To determine if H.pylori infection is significantly associated with recurrent abortion of unknown cause........

Study Overview

Status

Not yet recruiting

Detailed Description

3.Patients and methods

Study design:

Case Control study two groups (one group of 50 women with history of recurrent abortion and another group of 50 women without recurrent of abortion)

Study location:

the study will be conducted in Assiut university hospitals (women's health hospital) .

Study duration:

the study will be carried out from October 2025 till October 2026.

Sample size :

the calculated sample size for two groups 100 cases (one group of 50 women with history of recurrent abortion and another group of 50 women without recurrent of abortion).

4.Inclusion criteria

  • All woman with repeated abortion of Unknwon cause.
  • Not received H.pylori eradication therapy in prior 3 months .

    5.Exclusion criteria

  • Known uterine anatomical causes of abortion.
  • Current systemic antibiotic use and PPIs within 2 weeks.
  • Medical diseases as (Thyroid disorders , DM,HTN).
  • Antiphspholipid syndrome. 6.Methods
  • Case Control study at Assiut woman's heath hospital from October 2025 till October 2026.
  • Case Control study two groups (one group of women with history of recurrent abortion and another group of women without recurrent of abortion) by stool antigen test.

    7.All patients will be subjected to the following

  • Complete obstetric history , medical history, smoking ,alcohol, recent antibiotics ,PPIs , socioeconomic status
  • Laboratory samples :

H.pylori antigen in stool ,complete blood count , abdominopelvic ultrasound , urine analysis , liver and kidney function tests ,TSH , prolactin and any necessary investigation will be done.

Anti cardiolipin (IgM , IgG) ,Lupus anti coagulant and Anti B2 glycoproteinA1 (IgM, IgG) and 3D US on uterus . 8.Ethical considerations

  • All subjects will provide written informed consent to participate in the study .
  • The protocol of the study will be presented to the local ethics committee for approval.

    9.Statistical analysis

  • Statistical analysis will be performed using Spss version 23.

    10.References

  • 1. Malaty HM. Epidemiology of Helicobacter pylori infection. Best Pract Res Clin Gastroenterol 2007; 21: 205-214
  • 2. Suerbaum S, Michetti P. Helicobacter pylori infection. N Engl J Med 2002; 347: 1175-1186
  • 3. Chen MJ, Fang YJ, Wu MS, Chen CC, Chen YN, Yu CC et al. Application of Helicobacter pylori stool antigen test to survey the updated prevalence of Helicobacter pylori infection in Taiwan. 2020;35:233-40
  • 4. Ambühl LM, Baandrup U, Dybkær K,Blaakær J, Uldbjerg N, Sørensen S. Human papillomavirus infection as a possible cause of spontaneous abortion and spontaneous preterm delivery 2016;2016.
  • 5. Azami M, Nasirkandy MP, Mansouri A, Darvishi Z, Rahmati S, Abangah G, DehghanHR, Borji M, Abbasalizadeh S. GGollobal Prevelance of H.pylori infection in pregnant women: a systematic review and meta-analysis study. Int J Women's Health Reprod Sci. 2017;5:30-6.
  • 6. Practice Committee of the American Society for Reproductive Medicine. Definitions of infertility and recurrent pregnancy loss: a committee opinion. Fertil Steril. 2013 99:63.

Study Type

Observational

Enrollment (Estimated)

100

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

  • Name: Mostafa Gamal Ahmed Mostafa موشا -مركز اسيوط -محافظة اسيوط
  • Phone Number: 01095773806 01095773806
  • Email: Moustafa.15235564@med.aun.edu.eg

Study Contact Backup

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Sampling Method

Non-Probability Sample

Study Population

• All woman with repeated abortion of Unknwon cause.

Description

Inclusion Criteria• All woman with repeated abortion of Unknwon cause.

  • Not received H.pylori eradication therapy in prior 3 months .

Exclusion Criteria:

  • Known uterine anatomical causes of abortion.
  • Current systemic antibiotic use and PPIs within 2 weeks.
  • Medical diseases as (Thyroid disorders , DM,HTN).
  • Antiphspholipid syndrome.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
one group of women with history of recurrent abortion
another group of women without recurrent of abortion
h.pylori stool antigen

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
• To determine if H.pylori infection is significantly associated with recurrent abortion of unknown cause
Time Frame: baseline
baseline
H.pylori infection among women with recurrent abortion of unknown cause
Time Frame: the study will be carried out from October 2025 till October 2026
• To determine if H.pylori infection is significantly associated with recurrent abortion of unknown cause........
the study will be carried out from October 2025 till October 2026

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

December 1, 2025

Primary Completion (Estimated)

November 1, 2026

Study Completion (Estimated)

December 1, 2026

Study Registration Dates

First Submitted

November 22, 2025

First Submitted That Met QC Criteria

December 6, 2025

First Posted (Actual)

December 19, 2025

Study Record Updates

Last Update Posted (Actual)

December 19, 2025

Last Update Submitted That Met QC Criteria

December 6, 2025

Last Verified

December 1, 2025

More Information

Terms related to this study

Other Study ID Numbers

  • H.pylori infection e abortion

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Helicobacter Pylori Infection, Susceptibility to

Clinical Trials on H pylori eradication

Subscribe